Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Phapros TbkISX:PEHA -1.42%74 Debt-to-EBITDA is 10.92 as of Mar. 2026, which is 109% above its 10-year median of 5.23. GuruFocus rates ISX:PEHA with a GF Score™ of 74/100 and a GF Value™ of Rp381.22 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 685 Drug Manufacturers companies, PT Phapros Tbk ranks worse than 84.23% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for PT Phapros Tbk's Debt-to-EBITDA or its related term are showing as below:
ISX:PEHA'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.64 Med: 5.23 Max: 9.08
Current: 6.02
During the past 13 years, the highest Debt-to-EBITDA Ratio of PT Phapros Tbk was 9.08. The lowest was -2.64. And the median was 5.23.
ISX:PEHA's Debt-to-EBITDA is ranked worse than 84.23% of 685
companies
in the Drug Manufacturers industry
Industry Median: 1.58
vs ISX:PEHA: 6.02
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
PT Phapros Tbk Debt-to-EBITDA Related Terms
PT Phapros Tbk Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for PT Phapros Tbk's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:PEHA vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Phapros Tbk's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Phapros Tbk Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Phapros Tbk's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PT Phapros Tbk's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
PT Phapros Tbk (ISX:PEHA) has a Debt-to-EBITDA of 10.92 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PT Phapros Tbk. This is 109% above median its historical median of 5.23. According to the industry distribution chart, PT Phapros Tbk ranks #577 out of 685 companies in the Drug Manufacturers industry, placing it in the top 84.2%.
Is PT Phapros Tbk's Debt-to-EBITDA too high?
PT Phapros Tbk's current Debt-to-EBITDA of 10.92 is 109% above median its 10-year median of 5.23. The Drug Manufacturers industry median Debt-to-EBITDA is 1.58. PT Phapros Tbk's value of 10.92 is 591.1% above this industry median. Based on the distribution chart, PT Phapros Tbk ranks #577 out of 685 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PT Phapros Tbk has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Phapros Tbk's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PT Phapros Tbk ranks #577 out of 685 companies for Debt-to-EBITDA. This places PT Phapros Tbk in the lower half of its industry. The industry median Debt-to-EBITDA is 1.58. PT Phapros Tbk's value of 10.92 is 591.1% above this benchmark. While the company's 10-year median is 5.23 vs. the industry median of 1.58, PT Phapros Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.58, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Phapros Tbk's current Debt-to-EBITDA of 10.92 is 591.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PT Phapros Tbk. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Phapros Tbk's current Debt-to-EBITDA is 10.92, which is 109% above median its own 10-year median of 5.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Phapros Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Phapros Tbk (ISX:PEHA) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp381.22, compared to a current price of Rp278.00 — trading 27.1% below its estimated fair value. The current Debt-to-EBITDA is 10.92, which is 109% above median its 10-year median of 5.23 and 591.1% above the Drug Manufacturers industry median of 1.58. PT Phapros Tbk's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For PT Phapros Tbk (ISX:PEHA), the current Debt-to-EBITDA is 10.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Phapros Tbk (ISX:PEHA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Phapros Tbk stock appears to be undervalued.
The current stock price of Rp278.00 is trading 27.1% below its estimated GF Value™ of Rp381.22.
GuruFocus considers PT Phapros Tbk to be Modestly Undervalued.
Key valuation signals for ISX:PEHA:
Debt-to-EBITDA: 10.92 (109% above median its 10-year median of 5.23)
GF Value™: Rp381.22 vs. price of Rp278.00 (27.1% below fair value)
Industry Position: 591.1% above the Drug Manufacturers median (#577 of 685)
No single metric tells the full story. See the ISX:PEHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Phapros Tbk is a pharmaceutical company in Indonesia. The company is engaged in the industrial/manufacturing sector by producing and/or trading medicines, health instruments, chemical goods, and other similar goods in import, export, and other kinds of industry. The company operates through Over Counter (OTC), Ethical, Generic Drugs Bearing (OGB), and Toll Manufacturing segments. It derives maximum revenue from OGB segment.
74GF Score
Get the complete analysis for ISX:PEHA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:PEHA has been successfully added to your 
